๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent Fallopian Tube Carcinoma

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site๐Ÿ“ Scottsdale Mayo Clinic ยท Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). NCT06843447Phase 1, Phase 239 sites๐Ÿ“ New Haven๐Ÿ“ Louisville๐Ÿ“ Shreveport Merck Sharp & Dohme LLC ยท Tests: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) NCT03983226Phase 25 sites๐Ÿ“ Shanghai๐Ÿ“ Guangzhou๐Ÿ“ Hangzhou Shanghai Gynecologic Oncology Group ยท Tests: Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Nirapโ€ฆ Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Computed Tomography, Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomogrโ€ฆ Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer NCT04469764Phase 21 site๐Ÿ“ Los Angeles Jonsson Comprehensive Cancer Center ยท Tests: Abemaciclib, Anastrozole, Letrozole Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer NCT07667192n/a1 site๐Ÿ“ Zamoล›ฤ‡ Affidea Nu-med Center of Oncological DIagnostics and Therapy ยท Tests: Reirradiation, Total Ablative Strategy An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib NCT05887609Phase 26 sites๐Ÿ“ Irvine๐Ÿ“ Aurora๐Ÿ“ Chicago University of Colorado, Denver ยท Tests: Mirvetuximab Soravtansine-gynx, Olaparib APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion NCT04919629Phase 21 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Bevacizumab, Biopsy, Biospecimen Collection, Pegcetacoplan, Pembrolizumab A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab NCT04590326Phase 1, Phase 228 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Orange Regeneron Pharmaceuticals ยท Tests: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers NCT03564340Phase 1, Phase 254 sites๐Ÿ“ Birmingham๐Ÿ“ Boston๐Ÿ“ Boston Regeneron Pharmaceuticals ยท Tests: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer NCT07589543Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-DUALNK, Cyclophosphamide, Fludarabine HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069Phase 31 site๐Ÿ“ Beijing Hansoh BioMedical R&D Company ยท Tests: HS-20089, Paclitaxel, Doxorubicin, Topotecan Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406Phase 12 sites๐Ÿ“ Baltimore๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Quality-of-Life Assessment, Radiation Therapy, Talazoparib A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467Phase 3198 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Irvine Merck Sharp & Dohme LLC ยท Tests: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent) Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer NCT05236686NA1 site๐Ÿ“ Shanghai Shanghai Gynecologic Oncology Group ยท Tests: Hepato-celiac lymphadenectomy Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16) NCT07480954Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190Phase 228 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Hansoh BioMedical R&D Company ยท Tests: HS-20089 RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973Phase 21 site๐Ÿ“ Beijing Peking University Cancer Hospital & Institute ยท Tests: RC48+carboplatinยฑbevacizumab An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study NCT06855706NA1 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. NCT06434610Phase 217 sites๐Ÿ“ Beijing๐Ÿ“ Bengbu๐Ÿ“ Changsha Shanghai Jiaolian Drug Research and Development Co., Ltd ยท Tests: B013, Paclitaxel, Placebo Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRฮฑ, MUC16) pt2 NCT07617753Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Dual-target CAR-NK cell product, Cyclophosphamide, supportive IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence NCT07495124Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospeโ€ฆ ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649Phase 22 sites๐Ÿ“ Detroit๐Ÿ“ Flint Ira Winer ยท Tests: Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study NCT06295965n/a1 site๐Ÿ“ Seattle University of Washington ยท Tests: Non-Interventional Study A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers NCT06469281Phase 15 sites๐Ÿ“ Boston๐Ÿ“ Hackensack๐Ÿ“ Buffalo Regeneron Pharmaceuticals ยท Tests: 27T51, Cemiplimab, Bevacizumab Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377Phase 2484 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites๐Ÿ“ Buffalo๐Ÿ“ Houston Roswell Park Cancer Institute ยท Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Aโ€ฆ A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) NCT06994195Phase 31 site๐Ÿ“ Shanghai Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer NCT05071937Phase 21 site๐Ÿ“ Pittsburgh Alexander B Olawaiye, MD ยท Tests: ZEN003694, Talazoparib BP1001-A in Patients With Advanced or Recurrent Solid Tumors NCT04196257Phase 14 sites๐Ÿ“ Silver Spring๐Ÿ“ Detroit๐Ÿ“ Dallas Bio-Path Holdings, Inc. ยท Tests: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy